CN Patent

CN101478950B — Tmc278的水性悬浮液

Assigned to Janssen Sciences Ireland ULC · Expires 2013-02-06 · 13y expired

What this patent protects

本发明涉及用于通过肌内或皮下注射施用的药物组合物，其包含悬浮在水性可药用载体中的NNRTI化合物TMC278的微粒或纳米颗粒，以及涉及此类药物组合物在HIV感染的治疗和预防中的用途。

USPTO Abstract

本发明涉及用于通过肌内或皮下注射施用的药物组合物，其包含悬浮在水性可药用载体中的NNRTI化合物TMC278的微粒或纳米颗粒，以及涉及此类药物组合物在HIV感染的治疗和预防中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN101478950B
Jurisdiction
CN
Classification
—
Expires
2013-02-06
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Sciences Ireland ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.